Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | PLK1 | P53350 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746319 | 1.00 | HPGD (0.62) | HPGDGAAPLK1SMN1; SMN2POLB | |
| SCHEMBL28300251 | 0.92 | GAA (0.58) | HPGDGAAPLK1SMN1; SMN2POLB | |
| SCHEMBL2344909 | 0.85 | GAA (0.71) | GAAPLK1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL2650229 | 0.84 | POLB (0.72) | HPGDGAASMN1; SMN2POLBTYK2 | |
| SCHEMBL3140037 | 0.84 | HPGD (0.64) | HPGDSMN1; SMN2POLBTYK2NPC1 | |
| SCHEMBL29971293 | 0.84 | GAA (0.53) | HPGDGAAPLK1SMN1; SMN2MAPK1 | |
| SCHEMBL30339452 | 0.83 | PLK1 (0.53) | HPGDGAAPLK1POLBNPC1 | |
| SCHEMBL4155499 | 0.83 | PLK1 (0.53) | HPGDGAAPLK1POLBNPC1 | |
| SCHEMBL18763268 | 0.83 | POLB (0.61) | HPGDGAASMN1; SMN2POLBTYK2 | |
| SCHEMBL4815209 | 0.82 | HPGD (0.62) | HPGDGAASMN1; SMN2POLBTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114190632-A | Antibacterial breathable mask and preparation method thereof | 高守垒 | 2022-03-18 | — | — | CN | claimed |
| US-11066749-B2 | Corrosion inhibition of HCL treatment fluids with environmentally compatible solvent | HALLIBURTON ENERGY SERVICES, INC. (US) | 2021-07-20 | — | — | US | claimed |
| CN-112704292-A | Preparation method of antibacterial breathable mask | 高守垒 | 2021-04-27 | — | — | CN | claimed |
| US-20200173034-A1 | Corrosion Inhibition of HCL Treatment Fluids with Environmentally Compatible Solvent | HALLIBURTON ENERGY SERVICES, INC. (US) | 2020-06-04 | — | — | US | claimed |
| US-10604850-B2 | Corrosion inhibition of HCL treatment fluids with environmentally compatible solvent | HALLIBURTON ENERGY SERVICES, INC. (US) | 2020-03-31 | — | — | US | claimed |
| US-20180127882-A1 | Corrosion Inhibition of HCL Treatment Fluids with Environmentally Compatible Solvent | HALLIBURTON ENERGY SERVICES, INC. (US) | 2018-05-10 | — | — | US | claimed |
| US-20170253582-A1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | claimed |
| EP-3154964-A1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | The University of Kansas (US) | 2017-04-19 | — | — | EP | claimed |
| CN-106458939-A | Oxazolidine-based compound and selective androgen receptor agonist comprising same | 东亚ST株式会社 | 2017-02-22 | — | — | CN | claimed |
| WO-2016190865-A1 | CORROSION INHIBITION OF HCL TREATMENT FLUIDS WITH ENVIRONMENTALLY COMPATIBLE SOLVENT | HALLIBURTON ENERGY SERVICES, INC. (US) | 2016-12-01 | — | — | WO | claimed |
| WO-2015192099-A1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-12-17 | — | — | WO | claimed |
| EP-2646600-A1 | CORROSION INHIBITOR COMPOSITIONS COMPRISING REACTION PRODUCTS OF ALDEHYDES AND AMIDES AND RELATED METHODS | Halliburton Energy Services, Inc. (US) | 2013-10-09 | — | — | EP | claimed |
| US-8361937-B2 | Corrosion inhibitor compositions comprising reaction products of aldehydes and amides and related methods | HALLIBURTON ENERGY SERVICES, INC. (US) | 2013-01-29 | — | — | US | claimed |
| WO-2012072986-A1 | CORROSION INHIBITOR COMPOSITIONS COMPRISING REACTION PRODUCTS OF ALDEHYDES AND AMIDES AND RELATED METHODS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2012-06-07 | — | — | WO | claimed |
| US-20120142563-A1 | Corrosion Inhibitor Compositions Comprising Reaction Products of Aldehydes and Amides and Related Methods | HALLIBURTON ENERGY SERVICES, INC. (US) | 2012-06-07 | — | — | US | claimed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | claimed |
| US-5245004-A | ANHYDROUS POLYMERIZATION OF CAPROLACTAM WITH CATALYST, COCATALYST AND ACTIVATOR | UNITIKA LTD. (JP) | 1993-09-14 | — | — | US | claimed |
| EP-0522533-A1 | Process for polymerizing epsilon-caprolactam | UNITIKA LTD. (JP) | 1993-01-13 | — | — | EP | claimed |
| JP-55139333-A | — | — | None | — | — | JP | disclosed |
| US-3956391-A | Amino substituted tetrahydropleiadenes | SANDOZ, INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253582-A1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | HPGD 237/4885GAA 1042/4885PLK1 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.